Exclusive Summary

• Flurbiprofen Patch is a well-established topical NSAID with patents long expired, presenting minimal IP risk and a straightforward path for generic distribution partnerships across multiple markets.
• With over 1.7 billion musculoskeletal disease patients globally and accelerating aging demographics, demand for topical analgesic patches is large and growing, especially in Asia-Pacific, Middle East, and Latin America.
• The topical delivery route offers a compelling safety advantage over oral NSAIDs—significantly lower GI and cardiovascular risks—making it guideline-preferred (OARSI, EULAR) for elderly patients and those with contraindications to oral therapy.
• Chinese manufacturers offer 30–60% cost savings versus Japanese originator products, enabling distribution partners to achieve competitive pricing or higher margins in their local markets.
• The 20mg/40mg dual-strength portfolio covers a broad patient spectrum and supports differentiated market positioning in markets where competing topical NSAIDs (mainly diclofenac) are already crowded.